statistiche ricercatore

GROSSI, FRANCESCO

Distribuzione geografica

Continente	#
EU - Europa	4.228
NA - Nord America	2.207
AS - Asia	59
Continente sconosciuto - Info sul continente non disponibili	4
OC - Oceania	2
Totale	6.500

Salva come PNG Salva come JPEG

Nazione	#
IT - Italia	3.225
US - Stati Uniti d'America	2.204
IE - Irlanda	569
SE - Svezia	191
GB - Regno Unito	158
DE - Germania	44
IN - India	23
UA - Ucraina	15
FI - Finlandia	12
TR - Turchia	10
HK - Hong Kong	7
BE - Belgio	6
CN - Cina	6
SG - Singapore	6
VN - Vietnam	6
EU - Europa	4
CA - Canada	3
FR - Francia	3
AU - Australia	2
RU - Federazione Russa	2
AT - Austria	1
BG - Bulgaria	1
CH - Svizzera	1
JP - Giappone	1
Totale	6.500

Salva come PNG Salva come JPEG

Città	#
Milan	2.443
Dublin	569
Princeton	435
Fairfield	300
Rome	218
Wilmington	195
Ashburn	192
Nyköping	160
Chandler	131
San Diego	115
Woodbridge	110
Seattle	93
Ogden	86
Houston	81
Cambridge	74
London	62
Ann Arbor	56
Como	42
Pune	22
Norwalk	21
Chiswick	18
Kilburn	16
Redmond	13
Washington	13
Jacksonville	12
Prescot	8
Acton	7
New Bedfont	7
Brussels	6
Frankfurt am Main	6
Hounslow	6
Kowloon	6
Singapore	6
Southwark	6
Berlin	5
Boardman	5
Chicago	5
Islington	5
Los Angeles	5
Wandsworth	5
Helsinki	4
Lappeenranta	4
Varese	4
Boulder	3
Dearborn	3
Dong Ket	3
Mountain View	3
Toronto	3
Cassano d'Adda	2
Magnago	2
Moretta	2
Naples	2
Aachen	1
Beijing	1
Brescia	1
Bursa	1
Böblingen	1
Ceto	1
Denver	1
Esslingen am Neckar	1
Fayetteville	1
Gatchina	1
Genoa	1
Gorizia	1
Hefei	1
Izmir	1
Kocaeli	1
Lavis	1
Long Beach	1
Melbourne	1
Miami Beach	1
New York	1
Opfikon	1
Rapallo	1
Redwood City	1
Rozzano	1
San Mateo	1
Sofia	1
Stockholm	1
Torino	1
Treviso	1
Verona	1
Vienna	1
Wada	1
Yekaterinburg	1
Zhengzhou	1
Totale	5.634

Salva come PNG Salva come JPEG

Nome	#
ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin	142
Analysis of K-ras, p53, bcl-2 and Rb expression in non-small cell lung cancer cell lines.	92
Afatinib for the treatment of non-small cell lung cancer	64
Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy	63
DISRUPT: a randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer	59
Introduction of the beta isozyme of protein kinase C accelerates induced differentiation of murine erythroleukemia cells	48
Survival benefit with adjuvant chemotherapy in stage III microsatellite-high/deficient mismatch repair colon cancer: a systematic review and meta-analysis	47
Novel treatment strategies for early-stage lung cancer: The oncologist’s perspective	47
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation	46
Vinflunine for the treatment of non-small cell lung cancer	46
Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy	46
Afatinib for the treatment of advanced non-small-cell lung cancer	44
Advances in treatment of mesothelioma	44
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer	44
Update on the treatment of small cell lung cancer (SCLC)	44
Exosomes: a new horizon in lung cancer	43
Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab	42
Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study	42
Tumor microenvironment as a potential source of clinical biomarkers in non-small cell lung cancer: can we use enemy territory at our advantage?	42
The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib	42
COVID-19 vaccination in patients with classic Kaposi’s sarcoma	42
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis	41
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study	41
Oral Vinorelbine Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-Line Treatment for Patients with Advanced non- Squamous non- Small Cell Lung Cancer: a Cost Minimization Analysis in Twelve European Countries	41
Adjuvant chemotherapy for non-small cell lung cancer: Ready for clinical practice?	41
Hematopoietic growth factors in lung cancer	41
New perspectives for the pharmacological and biological therapy of small cell lung cancer	41
Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial	41
A review of clinical practice guidelines and treatment recommendations for cancer care in the COVID-19 pandemic	41
Recent advances in squamous non-small cell lung cancer: evidence beyond predictive biomarkers	40
Liquid biopsy in non-small cell lung cancer: highlights and challenges	40
The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer	40
Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds	39
Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy	39
Management of malignant pleural effusions	39
30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)	38
Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: A randomized study	38
Interaction between novel anticancer agents and radiation in non-small cell lung cancer cell lines	38
Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors	38
CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine	38
Free drugs in clinical trials and their potential cost saving impact on the National Health Service: a retrospective cost analysis in Italy	38
Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer.	38
Immune checkpoint inhibitors for treatment of small-cell lung cancer: a systematic review and meta-analysis	38
Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer	38
Potential cardiac risk of immune-checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects	37
Induction chemotherapy followed by concurrent standard radiotherapy and daily low dose cisplatin in locally advanced non-small-cell lung cancer	37
Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer	37
Looking for results in non-small-cell lung cancer: is bio-chemotherapy the right answer?	36
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052)	36
Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial.	36
Next generation sequencing in non-small cell lung cancer: new avenues toward the personalized medicine	36
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer	36
Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers	35
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes	35
IL-12 Can Target Human Lung Adenocarcinoma Cells and Normal Bronchial Epithelial Cells Surrounding Tumor Lesions	35
Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer	35
Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: A phase II trial from an Italian cooperative group	35
Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study	35
Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib	35
Impact of low-dose computed tomography screening on lung cancer mortality among asbestos-exposed workers	34
Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study	34
Adjuvant treatment for patients with incidentally resected limited disease small cell lung cancer-a retrospective study	34
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial	34
Identifying an optimum treatment strategy for patients with advanced non-small cell lung cancer	34
Oral vinorelbine plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of advanced non-squamous non-small-cell lung cancer: cost minimization analysis in 12 European countries	34
Managing patients with lung cancer - Common international guidelines must be developed	34
Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001)	34
Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview	34
Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: A review of the literature	34
Baseline characteristics and outcomes of cancer patients infected with sars-cov-2 in the lombardy region, italy (Aiom-l corona): A multicenter, observational, ambispective, cohort study	34
Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy	33
Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial	33
Pleural and peripheral lung lesions: comparison of US- and CT-guided biopsy	33
Ramucirumab: preclinical research and clinical development	33
CD133-Positive Cells from Non-Small Cell Lung Cancer Show Distinct Sensitivity to Cisplatin and Afatinib	33
Maintenance chemotherapy in non-small cell lung cancer	33
Systemic drug therapy of malignant pleural mesothelioma.	33
Future Scenarios for the Treatment of Advanced Non-Small Cell Lung Cancer: Focus on Taxane-Containing Regimens	33
Phase II Study of Sunitinib in Patients with Non-small Cell Lung Cancer and Irradiated Brain Metastases	33
Synthesis of new oxathiazinane dioxides and their in vitro cancer cell growth inhibitory activity	33
Information given to cancer patients on diagnosis, prognosis and treatment: the clinical oncologist's perspective	33
The clinical management of early and advanced colorectal cancer	33
Predictive and prognostic significance of neuron-specific enolase (NSE) in non-small cell lung cancer.	33
Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer	33
IDH signalling pathway in cholangiocarcinoma: From biological rationale to therapeutic targeting	33
COVID-19 vaccination mimicking lymph-node progression in a patient with melanoma: A case report	33
Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases	32
PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells	32
Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial	32
NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer	32
Successful treatment of lung adenocarcinoma with gefitinib based on EGFR gene amplification	32
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial	32
Mechanism of action of fluoropyrimidines: Relevance to the new developments in colorectal cancer chemotherapy	32
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial	32
Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffin-embedded lung adenocarcinoma samples	32
Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non Small-Cell Lung Cancer	32
Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer	32
Role of microRNAs in malignant mesothelioma	32
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy	32
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study	32
Totale	3.922

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	68.558
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	68.558

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2018/2019	19	0	0	0	0	0	0	0	0	0	0	10	9
2019/2020	59	4	3	3	12	4	5	7	7	6	4	0	4
2020/2021	41	0	5	0	5	0	10	0	4	4	3	2	8
2021/2022	1.833	0	5	1	0	430	190	192	151	232	186	105	341
2022/2023	1.155	225	49	70	40	78	310	4	69	84	176	16	34
2023/2024	3.862	483	689	646	787	905	116	26	52	146	12	0	0
Totale													7.022